TRIM33 and cancer: For anti-CCAR1, which is also frequently targeted but is less frequently mutated in cancer (2.1% of cancers in COSMIC), the observations here that CCAR1 and TIF1-γ are in a molecular complex strongly indicate that CCAR1 is targeted through intermolecular spreading.